Login Register Cart 0
Generic placeholder image

Current Computer-Aided Drug Design

Editor-in-Chief

ISSN (Print): 1573-4099
ISSN (Online): 1875-6697

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

New Resensitizers for the Nicotinic Acetylcholine Receptor by Ligand-Based Pharmacophore Modeling

Author(s): Thomas Wein, Klaus T. Wanner *, Sebastian Rappenglück, Sonja Sichler, Karin V. Niessen, Thomas Seeger, Franz Worek and Horst Thiermann

Volume 15, Issue 1, 2019

Page: [104 - 109] Pages: 6

DOI: 10.2174/1573409914666180703120201

Price: $65

Abstract

Introduction: Irreversible inhibition of the acetylcholinesterase upon intoxication with organophosphorus compounds leads to an accumulation of acetylcholine in the synaptic cleft and a subsequent desensitization of nicotinic acetylcholine receptors which may ultimately result in respiratory failure. A direct intervention at the nicotinic acetylcholine receptor (nAChR) was proposed as an alternative therapeutic approach to the treatment with atropine and oximes.

Methods: The bispyridinium compound MB327 has been found to recover functional activity of nAChR thus representing a promising starting point for the development of new drugs for the treatment of organophosphate poisoning. Recent solid-supported membrane-based electrophysiological experiments have identified symmetrically substituted bispyridinium compounds e.g. MB327, MB583, and PTM0001 that are able to resensitize nAChR of Torpedo californica. In addition, six compounds have been found not to show any resensitizing potential and were thus classified as inactive. This set of active and inactive bispyridinium compounds was taken to develop a pharmacophore model and in silico screening of a virtual database of bispyridinium compounds to identify new compounds that are able to restore the functional activity of desensitized nAChR.

Results: Screening of a virtual compound database of symmetrically substituted bispyridinium compounds with the derived pharmacophore yielded several promising compounds which satisfy the pharmacophore and ought to have the same or even better resensitizing effect on nAChR as the parent compound MB327.

Keywords: Nicotinic acetylcholine receptor, nAChR, desensitization, Torpedo californica, bispyridinium compounds, pharmacophore modeling, virtual screening.

« Previous Next »
Graphical Abstract

[1]
Holmstedt, B. Pharmacology of Organophosphorus Cholinesterase Inhibitors.Pharmacol. Rev. 1959, 11 (3), 567 LP-688,
[2]
Thiermann, H.; Seeger, T.; Gonder, S.; Herkert, N.; Antkowiak, B.; Zilker, T.; Eyer, F.; Worek, F. Assessment of Neuromuscular Dysfunction during Poisoning by Organophosphorus Compounds. Chem. Biol. Interact., 2010, 187(1-3), 265-269.
[3]
McDonough, J.H.; Shih, T-M. Atropine and Other Anticholinergic Drugs.Chemical Warfare Agents; John Wiley & Sons, Ltd, 2007, pp. 287-303.
[4]
Worek, F.; Thiermann, H.; Szinicz, L.; Eyer, P. Kinetic analysis of interactions between human acetylcholinesterase, structurally different organophosphorus compounds and oximes. Biochem. Pharmacol., 2004, 68(11), 2237-2248.
[5]
Sheridan, R.D.; Smith, A.P.; Turner, S.R.; Tattersall, J.E.H. Nicotinic antagonists in the treatment of nerve agent intoxication. J. R. Soc. Med., 2005, 98(3), 114-115.
[6]
Albuquerque, E.X.; Pereira, E.F.R.; Alkondon, M.; Rogers, S.W. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol. Rev., 2009, 89(1), 73-120.
[7]
Hurst, R.; Rollema, H.; Bertrand, D. Nicotinic acetylcholine receptors: From basic science to therapeutics. Pharmacol. Ther., 2013, 137(1), 22-54.
[8]
Seeger, T.; Eichhorn, M.; Lindner, M.; Niessen, K.V.; Tattersall, J.E.H.; Timperley, C.M.; Bird, M.; Green, A.C.; Thiermann, H.; Worek, F. Restoration of Soman-Blocked Neuromuscular Transmission in Human and Rat Muscle by the Bispyridinium Non-Oxime MB327 in vitro. Toxicology, 2012, 294(2-3), 80-84.
[9]
Turner, S.R.R.; Chad, J.E.E.; Price, M.; Timperley, C.M.M.; Bird, M.; Green, A.C.; Tattersall, J.E.H.E.H. Protection against nerve agent poisoning by a noncompetitive nicotinic antagonist. Toxicol. Lett., 2011, 206(1), 105-111.
[10]
Niessen, K.V.; Muschik, S.; Langguth, F.; Rappenglück, S.; Seeger, T.; Thiermann, H. Functional analysis of torpedo californica nicotinic acetylcholine receptors in multiple activation states by SSM-based electrophysiology. Toxicol. Lett., 2016, 247, 1-10.
[11]
Niessen, K.V.; Tattersall, J.E.H.; Timperley, C.M.; Bird, M.; Green, C.; Seeger, T.; Thiermann, H.; Worek, F. Interaction of bispyridinium compounds with the orthosteric binding site of human α7 and torpedo californica nicotinic acetylcholine receptors (nAChRs). Toxicol. Lett., 2011, 206(1), 100-104.
[12]
Yang, S-Y. Pharmacophore modeling and applications in drug discovery: Challenges and recent advances. Drug Discov. Today, 2010, 15(11-12), 444-450.
[13]
Wermuth, C.G.; Ganellin, C.R.; Lindberg, P.; Mitscher, L.A. Glossary of Terms Used in. Pure Appl. Chem., 1979, 51(8), 1129-1143.
[14]
Güner, O.; Clement, O.; Kurogi, Y. Pharmacophore Modeling and Three Dimensional Database Searching for Drug Design Using Catalyst: Recent Advances. Curr. Med. Chem., 2004, 11, 2991-3005.
[15]
Kurogi, Y.; Güner, O.F. Pharmacophore modeling and three-dimensional database searching for drug design using catalyst. Curr. Med. Chem., 2001, 8, 1035-1055.
[16]
Chemaxon. MarvinSketch 15.10.5.0. Chemaxon 2015.
[17]
Smellie, A.; Teig, S.L.; Towbin, P. Poling: Promoting conformational variation. J. Comput. Chem., 1995, 16(2), 171-187.
[18]
Smellie, A.; Kahn, S.D.; Teig, S.L. Analysis of conformational coverage. 1. validation and estimation of coverage. J. Chem. Inf. Comput. Sci., 1995, 35, 285-294.
[19]
Smellie, A.; Kahn, S.D.; Teig, S. Analysis of Conformational Coverage. 2. applications of conformational models. J. Chem. Inf. Comput. Sci., 1995, 35, 295-304.
[20]
Accelrys Software Inc Discovery Studio Client 4.1.0. 2014. .
[21]
Sichler, S.; Höfner, G.; Rappenglück, S.; Wein, T.; Niessen, K.V.; Seeger, T.; Worek, F.; Thiermann, H.; Paintner, F.F.; Wanner, K.T. Development of MS Binding Assays Targeting the Binding Site of MB327 at the nicotinic acetylcholine receptor. Toxicol. Lett., 2017, 293, 172-183.
[22]
Rappenglück, S.; Sichler, S.; Höfner, G.; Wein, T.; Niessen, K.V.; Seeger, T.; Paintner, F.F.; Worek, F.; Thiermann, H.; Wanner, K.T. Synthesis of a novel series of structurally different mb327 derivatives and their affinity characterization at the nicotinic acetylcholine receptor. ChemMedChem, 2018, 13(17), 1806-1816.

Rights & Permissions Print Cite
Article Metrics
80
7
1
© 2024 Bentham Science Publishers | Privacy Policy